Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

Delayed Quote. Delayed  - 02/12 04:02:06 pm
16.64 USD   +0.36%
02/09 BOSTON SCIENTIF : Medicare gives boost to Boston Scientific's device..
02/09 BOSTON SCIENTIF : EMDT - Bos Sci Optimistic on Watchman as It Awaits..
02/08 BOSTON SCIENTIF : Announces Medicare Will Cover WATCHMAN™ Left..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Boston Scientific : Announces Results for Fourth Quarter and Full Year Ended December 31, 2015

02/11/2016 | 05:41pm US/Eastern

By a News Reporter-Staff News Editor at Investment Weekly News -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant currency basis, excluding divested businesses) and 5 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.26 for the period, compared to $0.22 a year ago, and reported a GAAP loss of $(0.11) per share, compared to a GAAP loss of $(0.23) a year ago.

https://photos.prnewswire.com/prnvar/20160203/329537LOGO

For the year ended December 31, 2015, the company achieved full year sales of $7.477 billion, representing 8 percent operational revenue growth and 1 percent revenue growth on a reported basis. The company delivered full year adjusted earnings per share of $0.93, compared to $0.84 in 2014 and reported a GAAP loss of $(0.18) per share, compared to a GAAP loss of $(0.09) in the prior year period.

"Our accomplishments in 2015 demonstrate our continued momentum and track record of consistent performance across our businesses and geographies," said Mike Mahoney, president and chief executive officer, Boston Scientific. "The products and programs we brought to market through organic development and acquisitions, complemented by our innovative pipeline and continued global expansion, will benefit even more patients in 2016 and beyond."

Keywords for this news article include: Finance, Boston Scientific Corporation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Business Newsletters

React to this article
Latest news on BOSTON SCIENTIFIC CORPORAT
02/11 BOSTON SCIENTIFIC : Announces Results for Fourth Quarter and Full Year Ended Dec..
02/11 BOSTON SCIENTIFIC : Trademark Application for "ONCOZENE" Filed
02/11 BOSTON SCIENTIFIC : Trademark Application for "EMBOZENE" Filed by Boston Scienti..
02/11 BOSTON SCIENTIFIC : An Application for the Trademark "EMBOZENE MICROSPHERES" Has..
02/11 BOSTON SCIENTIFIC : Findings from Boston Scientific Corporation Broadens Underst..
02/09 BOSTON SCIENTIFIC : Medicare gives boost to Boston Scientific's device to help p..
02/09 BOSTON SCIENTIFIC : EMDT - Bos Sci Optimistic on Watchman as It Awaits Reimburse..
02/08 BOSTON SCIENTIFIC : Announces Medicare Will Cover WATCHMAN™ Left Atrial Ap..
02/08 BOSTON SCIENTIFIC : Announces Medicare Will Cover WATCHMAN(TM) Left Atrial Appen..
02/08 BOSTON SCIENTIFIC : Combine Solicitation - Service Maintenance AngioJet Ultra Th..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials